A Phase 4 interventional study of teicoplanin in Staphylococcal Infections, sponsored by National Taiwan University Hospital. Status unknown at 1 site in Taiwan. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2006-08-24.
Sponsored by National Taiwan University Hospital · Phase 4, Interventional, and Treatment
The purpose of this study is to determine whether the standard dosage of teicoplanin is adequate to produce timely the trough level > 10 mg/L, which is considered to be effective in the treatment of methicillin-resistant Staphyllococcus aureus (MRSA) bacteremia.
In our hospital, the minimum inhibitory concentration of 100 MRSA isolates in 2003 for teicoplanin is 2 mg/L. Due to its time-dependant bacteriocidal effect, the trough level should exceed 10 mg/L, particularly in the elderly, for MRSA bacteremia. However, it is known that standard dosage of teicoplanin often produces inadequate serum trough levels, and MRSA infections may recurred. Therefore, to evaluate the loading dose required to achieve therapeutic concentration timely, we compare the trough levels between those given standard dose (6 mg/Kg) and those given increasing loading dose (12 mg/Kg). We also monitor the occurrence of adverse drug effects and clinical response.
273 studies on the registry are indexed under Staphylococcal Infections; 29 are open to participants now.
This study's enrollment of 20 is below the median of 120 across 177 interventional studies indexed under Staphylococcal Infections.
Browse Staphylococcal Infections studies →National Taiwan University Hospital is the lead sponsor of 2,563 studies on the registry; 569 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
the proportion of the trough level attaining 10 mg/L at different timing
the occurrence of adverse drug effects
the correlation between the trough level and the patients' characteristics
This study is status unknown, as verified in Aug 2006. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Taiwan University Hospital